Staar Surgical Co(STAA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 349.32 | EPS (ttm) | 0.07 | Insider Own | 39.53% | Shs Outstand | 50.1M | Perf Week | 6.17% |
| Market Cap | 1.16B | Forward P/E | 42.47 | EPS next Y | 88.23% | Insider Trans | - | Shs Float | 30.3M | Perf Month | 13.26% |
| Enterprise Value | 1.02B | PEG | - | EPS next Q | 0.05 | Inst Own | 73.49% | Short Float | 12.33% | Perf Quarter | 2.52% |
| Income | 0.00B | P/S | 3.43 | EPS this Y | 129.06% | Inst Trans | 0.23% | Short Ratio | 4.11 | Perf Half Y | -12.93% |
| Sales | 0.34B | P/B | 3.19 | EPS next 5Y | - | ROA | 0.84% | Short Interest | 3.74M | Perf YTD | 0.61% |
| Book/sh | 7.29 | P/C | 6.42 | EPS past 3/5Y | - | ROE | 1.09% | 52W High | -35.24% ($35.87) | Perf Year | -11.57% |
| Cash/sh | 3.62 | P/FCF | - | Sales past 3/5Y | -5.57% 7.93% | ROIC | 0.97% | 52W Low | 49.05% ($15.59) | Perf 3Y | -39.25% |
| Dividend Est. | - | EV/EBITDA | 14.4 | EPS Y/Y TTM | 103.91% | Gross Margin | 74.76% | Volatility(W/M) | 4.08% 3.8% | Perf 5Y | -80.75% |
| Dividend TTM | - | EV/Sales | 3 | Sales Y/Y TTM | 51.3% | Oper. Margin | 18% | ATR (14) | 0.93 | Perf 10Y | 161.01% |
| Dividend Ex-Date | - | Quick Ratio | 4.03 | EPS Q/Q | 146.1% | Profit Margin | 1.13% | RSI (14) | 57.62 | Recom | 2.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.66 | Sales Q/Q | 111.04% | SMA20 | 4.63% ($22.2) | Beta | 1.24 | Target Price | $28.25 |
| Payout | - | Debt/Eq | 0.1 | Earnings | 2026/11/4 | SMA50 | 3.82% ($22.38) | Rel Volume | 0.82 | Prev Close | $22.61 |
| Employees | 957 | LT Debt/Eq | 0.08 | EPS/Sales Surpr. | -27.73% 3.24% | SMA200 | -1.34% ($23.55) | Avg Volume(3M) | 0.91M | Price | $23.23 |
| IPO | 1983/7/7 | Option/Short | Yes/Yes | Trades | 6688 | Volume | 748,952 | Change | 2.74% |
👁️ STAAR Surgical (STAA) is a U.S. ophthalmic medical device company that specializes in the development and manufacturing of Implantable Collamer Lenses (ICLs) for vision correction. Its flagship product, the EVO Visian ICL, corrects refractive errors such as myopia and astigmatism by inserting a lens into the eye rather than reshaping the cornea like LASIK or LASEK, and it has an extensive track record of cumulative implantations. The company has built a differentiated position in the high-myopia patient segment, where LASIK procedures are difficult to perform.
Over the past 1 year, roughly in the middle
35% below its 1-year high.
Traded about as much as usual. That is 82% of its average volume.
Next earnings report: November 4
8 days to go.
STAA earns at a steady pace
Of every $100 in sales, $18.00 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +129.1% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $4,247. Peers typically go for $1,968. Compared with its own 4-year average, it is 205% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -80.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 73.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #28 of 51 in the industry
Based on market cap of $1B.
LMAT#24 Lemaitre Vascular Inc $2B PER 30.0 
XRAY#25 DENTSPLY Sirona Inc $2B PER - 
KMTS#26 Kestra Medical Technologies Ltd $2B PER - 
AZTA#27 Azenta Inc $2B PER - STAA#28 Staar Surgical Co $1B PER 349.3 
FAQ
What kind of company is STAA?
STAA belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of STAA?
The market cap of STAA is approximately $1.2B, ranking 2,453 within its sector.
What is the P/E ratio of STAA?
STAA has a P/E ratio of approximately 349.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for STAA?
STAA has recorded a 52-week high of $35.87 and a low of $15.59.
